Clinical Trials Directory

Trials / Completed

CompletedNCT02245503

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Comorbidity and Comedication During Prescription of ALNA® (Tamsulosin) for Patients With BPH (Benign Prostatic Hyperplasia)

Status
Completed
Phase
Study type
Observational
Enrollment
7,391 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).

Conditions

Interventions

TypeNameDescription
DRUGTamsulosin

Timeline

Start date
2003-05-01
Primary completion
2003-10-01
First posted
2014-09-19
Last updated
2014-09-19

Source: ClinicalTrials.gov record NCT02245503. Inclusion in this directory is not an endorsement.

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH) (NCT02245503) · Clinical Trials Directory